-
公开(公告)号：US11883371B2
公开(公告)日：2024-01-30
申请号：US17210205
申请日：2021-03-23
CPC分类号： A61K31/12 , G01N33/6893 , G01N2800/7009
摘要： The present invention involves a novel method for treatment of chronic kidney disease comprising administering a compound that induces a stress protein response in a patient, and administering a potent antioxidant if the patent's response is below a predefined level. It also involves a quantitative measure for determining a patient's antioxidant reserve capacity.
-
公开(公告)号：US11834471B2
公开(公告)日：2023-12-05
申请号：US17979490
申请日：2022-11-02
IPC分类号： C07H23/00 , A61K9/00 , A61K9/08 , A61K31/409
CPC分类号： C07H23/00 , A61K9/0019 , A61K9/08 , A61K31/409
摘要： The present invention involves a novel aqueous iron composition. The aqueous iron composition includes iron sucrose and bicarbonate. The aqueous iron composition of the invention exhibits enhanced renal protective effects relative to conventional iron sucrose compositions.
-
公开(公告)号：US12115138B2
公开(公告)日：2024-10-15
申请号：US16811759
申请日：2020-03-06
IPC分类号： A61K31/12 , A61K9/127 , A61K31/145 , A61K31/16 , A61K31/355 , A61K31/375 , A61K31/385 , A61K31/7048 , A61K47/10 , A61K47/24 , A61K47/34
CPC分类号： A61K31/12 , A61K9/127 , A61K31/145 , A61K31/16 , A61K31/355 , A61K31/375 , A61K31/385 , A61K31/7048 , A61K47/10 , A61K47/24 , A61K47/34
摘要： The present invention relates to novel tetrahydrocurcumin (THCu) compositions, novel methods of manufacturing, and methods of using these compositions for therapeutic applications. The novel synthetic pathway(s) result in THCu compositions that generally lack hexahydrocurcumin (HHC), and include an improved impurity profile with reduced additional species that are generally present in hydrogenated curcumin compositions.
-
公开(公告)号：US20220079984A1
公开(公告)日：2022-03-17
申请号：US17472954
申请日：2021-09-13
IPC分类号： A61K33/26 , A61K39/395 , A61K31/7068 , A61K38/21 , A61K33/243 , A61K31/675 , A61K31/519 , A61K31/409 , A61K49/10 , A61P13/12
摘要： The present invention involves a novel method for treatment of cancer that involves co-administration of iron sucrose and/or a protoporphyrin such as tin protoporphyrin in an amount sufficient to protect a patient's kidney against cytotoxicity of a chemotherapeutic agent.
-
公开(公告)号：US12042501B2
公开(公告)日：2024-07-23
申请号：US17860872
申请日：2022-07-08
IPC分类号： A61K31/555 , A61K47/18 , A61K47/26 , A61P31/12
CPC分类号： A61K31/555 , A61K47/18 , A61K47/26 , A61P31/12
摘要： The inactivation of BK virus in patients diagnosed with BK virus, those receiving a kidney that is infected or suspected of being infected by BK virus, or in the transplanted kidney before, during, and/or after transplant surgery is described.
-
公开(公告)号：US20240166671A1
公开(公告)日：2024-05-23
申请号：US18363548
申请日：2023-08-01
IPC分类号： C07F7/22 , A61K31/555 , A61K33/26 , A61P41/00
CPC分类号： C07F7/2284 , A61K31/555 , A61K33/26 , A61P41/00 , C07F7/2296
摘要： Novel Stannic protoporfin compositions exhibiting high purity and other characteristics, including a novel solubility profile and visual indicators suggesting increase pharmacological activity, including enhanced antiviral activity. Also disclosed are novel processes for making Stannic protoporfin according to a process that requires fewer steps than known processes.
-
公开(公告)号：US11435364B2
公开(公告)日：2022-09-06
申请号：US16422156
申请日：2019-05-24
IPC分类号： G01N33/68 , A61K31/277 , A61K31/409 , A61K33/26
摘要： The p21 biomarker is utilized in the evaluation of whether a patient is suffering from kidney injury or failure, and can be used in methods of treating kidney injury or failure by determining the appropriateness of one or more of initiating renal replacement therapy, withdrawing delivery of compounds that are known to be damaging to the kidney, delaying or avoiding procedures that are known to be damaging to the kidney, and modifying diuretic administration.
-
公开(公告)号：US20240226144A1
公开(公告)日：2024-07-11
申请号：US18407130
申请日：2024-01-08
摘要： Methods of treating patients before a scheduled insult such as surgy by administering a combination of stannic protoporfin and iron sucrose are provided. The present methods provide protection to photosensitive patients and those susceptible to post-operative complications.
-
公开(公告)号：US11965896B2
公开(公告)日：2024-04-23
申请号：US17873968
申请日：2022-07-26
IPC分类号： G01N33/68 , A61K31/277 , A61K31/409 , A61K33/26
CPC分类号： G01N33/6893 , A61K31/277 , A61K31/409 , A61K33/26 , G01N2800/347
摘要： The p21 biomarker is utilized in the evaluation of whether a patient is suffering from kidney injury or failure, and can be used in methods of treating kidney injury or failure by determining the appropriateness of one or more of initiating renal replacement therapy, withdrawing delivery of compounds that are known to be damaging to the kidney, delaying or avoiding procedures that are known to be damaging to the kidney, and modifying diuretic administration.
-
公开(公告)号：US20240108589A1
公开(公告)日：2024-04-04
申请号：US18530782
申请日：2023-12-06
CPC分类号： A61K31/12 , G01N33/6893 , G01N2800/7009
摘要： The present invention involves a novel method for treatment of chronic kidney disease comprising administering a compound that induces a stress protein response in a patient, and administering a potent antioxidant if the patent's response is below a predefined level. It also involves a quantitative measure for determining a patient's antioxidant reserve capacity.
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.014 秒)
